Taevas
Pharmaceuticals · Global Coverage
Global Market Entry for Pharmaceuticals
Taevas navigates multi-jurisdiction drug registration, distributor access, and physician adoption so your pharmaceutical brand reaches patients faster and compliantly across every target market.
GMP Certified
ISO 9001
GDPR Compliant
GLOBAL DRUG ACCESS
Pharmaceuticals Market Entry Platform
340+
Drug Registrations Filed
24+
Regulatory Markets Covered
180+
Distributor & Hospital Partners
8+ years
Pharmaceutical Market Access Experience
The Challenge
Most Pharmaceuticals Firms Stop at Approval
Securing a drug registration is only the first hurdle. Pharmaceutical brands entering new markets face layered pricing controls, opaque distributor ecosystems, and physician trust barriers that can stall a launch for years. Without in-country intelligence and relationships, even approved molecules fail to reach their commercial potential.
01·of first-time pharma filings require resubmission due to dossier gaps
Regulatory Complexity Across Jurisdictions
Every market demands its own dossier format, bioequivalence data standards, and labelling language. Agencies such as the CDSCO, SFDA, MOH GCC, and NMPA each apply distinct timelines and technical requirements. A single missing document can reset a review cycle by 12 months or more, burning cash and delaying patient access.
Time to Market Comparison
Without Taevas18-24 months
With Taevas8-12 months
Up to 40%
Approval Cycle Reduction
Under 10%
Resubmission Rate
How Taevas Solves This
Taevas prepares jurisdiction-specific CTD dossiers with pre-submission agency liaison to eliminate avoidable resubmissions.
0x
Faster Market Entry
0
In-Country Regulatory Teams
0+
Drug Registrations Managed
Product Categories
Therapeutic Categories
Driven by evidence-based formulations, regulatory approvals, and widespread physician adoption across key therapy areas.
Cardiology
Antihypertensives, statins, anticoagulants, and antiarrhythmics targeting cardiovascular disease burden globally.
Diabetology
Oral hypoglycaemics, insulin analogues, and GLP-1 receptor agonists addressing rising global diabetes prevalence.
Oncology
Cytotoxic agents, targeted therapies, and immunoncology drugs requiring strict cold-chain and specialised oncology channel access.
Neurology & Psychiatry
Antiepileptics, antidepressants, antipsychotics, and MS therapies with complex central nervous system regulatory pathways.
Gastroenterology
Proton pump inhibitors, IBD biologics, and motility agents addressing high-prevalence GI disorders across all age groups.
Respiratory
Inhaled corticosteroids, bronchodilators, and leukotriene modifiers for asthma and COPD management in key markets.
Dermatology
Topical and systemic agents for acne, psoriasis, eczema, and fungal infections with strong OTC and Rx segments.
Orthopedics & Pain Management
NSAIDs, opioid analgesics, muscle relaxants, and topical pain formulations subject to controlled substance regulations.
Infectious Diseases
Antibiotics, antivirals, antifungals, and antiparasitics governed by antimicrobial stewardship policies in each market.
Gynecology & Obstetrics
Hormonal contraceptives, fertility treatments, and maternal health drugs with market-specific prescribing restrictions.
Urology
Alpha-blockers, PDE5 inhibitors, and overactive bladder agents addressing benign prostatic hyperplasia and incontinence.
Pediatrics
Age-appropriate formulations including oral suspensions and paediatric dosing requiring dedicated clinical safety data packages.
Prescription Drugs
Ethical pharmaceutical brands requiring physician detailing, hospital formulary listing, and schedule-specific regulatory compliance.
Over the Counter
Self-care and OTC switches benefiting from retail pharmacy networks, consumer marketing, and simplified registration pathways.
Biologics & Biosimilars
Large-molecule biologics and biosimilar comparability studies demanding advanced manufacturing compliance and specialised cold-chain logistics.
Vaccines
Preventive immunisation products requiring national immunisation programme inclusion, ultra-cold-chain, and public tender participation.
Injectables
Sterile parenteral formulations including IV, IM, and SC presentations subject to stringent aseptic manufacturing and import controls.
Generic Medicines
Bioequivalent generic formulations competing on price and formulary positioning within government and private payer reimbursement schemes.
Our Services
Nine Services. One Team. Complete Access.
Available individually or as a full end-to-end market entry programme.
Market Intelligence
Competitive landscape analysis, therapy-area epidemiology, pricing benchmarks, and prescriber segmentation specific to your target pharmaceutical markets.
Product Registration
End-to-end CTD dossier preparation, bioequivalence data management, and liaison with drug regulatory authorities including CDSCO, SFDA, NMPA, and MOH bodies.
Legal Representation
Appointment of local authorised representatives and marketing authorisation holders to satisfy in-country legal presence requirements for pharmaceutical imports.
Imports & Shipments
GDP-compliant pharmaceutical import management including temperature-controlled freight, customs clearance, and controlled substance documentation across all markets.
Warehousing & Inventory
Licensed pharmaceutical warehousing with ambient, refrigerated, and frozen storage zones, batch tracking, and expiry management aligned to local GMP standards.
Distributor Support
Identification, qualification, and ongoing management of pharmaceutical wholesalers, hospital distributors, and pharmacy chains across 24+ markets.
Local Manufacturing
Contract manufacturing and local packaging partnerships to meet local content requirements, reduce import duties, and improve supply chain resilience for your formulations.
Marketing & Brand
Physician detailing programmes, KOL engagement, CME event management, and compliant digital promotion tailored to pharmaceutical advertising regulations in each market.
Sales Support
Deployment of in-country medical sales representatives, hospital formulary listing support, and tender management to drive prescription volume and market share growth.
Regulatory Landscape
We Know Every Regulatory Authority
| Market | Regulatory Body |
|---|---|
🇮🇳India | CDSCO (Central Drugs Standard Control Organisation) |
🇨🇳China | NMPA (National Medical Products Administration) |
🇸🇦Saudi Arabia | SFDA (Saudi Food & Drug Authority) |
🇦🇪United Arab Emirates | MOH UAE / Dubai Health Authority (DHA) |
🇪🇺European Union | EMA (European Medicines Agency) / National Competent Authorities |
🇧🇷Brazil | ANVISA (Agência Nacional de Vigilância Sanitária) |
🇮🇩Indonesia | BPOM (Badan Pengawas Obat dan Makanan) |
🇿🇦South Africa | SAHPRA (South African Health Products Regulatory Authority) |
Our Process
Six Phases to Market Success
Click any phase to explore. Regulatory and commercial workstreams run in parallel.
Phase 01 of 06
Market Assessment
Market ResearchCompetitive Intelligence
What We Do
We conduct a comprehensive analysis of the target market including therapy-area epidemiology, competitive landscape, pricing environment, and reimbursement pathways to establish commercial viability before any investment is committed.
Taevas Advantage
Taevas in-country analysts deliver primary research alongside published data, giving you ground-truth insight unavailable from desk research alone.
1 / 6
Geographic Coverage
24 Markets With In-Country Specialists
Who This Is For
Built for These Pharmaceuticals Leaders
Mid-to-large pharmaceutical manufacturer
International Expansion Director
You are responsible for entering 3-5 new markets per year with an established product portfolio. You need a reliable partner who can manage multi-jurisdiction regulatory filings simultaneously, deliver local market intelligence, and activate commercial channels without requiring you to build in-country teams from scratch. Missed timelines directly impact your revenue targets.
Taevas acts as your full in-country infrastructure across all target markets, from dossier to first prescription, under a single accountable engagement.
Pharmaceutical brand seeking licensing or distribution
Business Development Manager
You are evaluating whether to license, co-promote, or self-distribute a molecule in markets where your organisation has no existing presence. You need robust market sizing data, a realistic regulatory timeline, and introductions to credible distribution partners to build your internal business case and board approval. Speed and accuracy of intelligence are critical.
Taevas delivers market feasibility reports, regulatory roadmaps, and qualified distributor introductions within weeks to accelerate your decision-making cycle.
Generic pharmaceutical company or biosimilar developer
Generic & Biosimilar Portfolio Head
You manage a pipeline of off-patent molecules or biosimilar candidates targeting high-volume markets where price competition is intense and formulary positioning is decisive. You need a partner who understands abbreviated registration pathways, government tender processes, and hospital procurement cycles to maximise volume and margin in each market.
Taevas maps abbreviated registration routes, tender calendars, and public procurement frameworks so your generics reach formulary position ahead of competitors.
Why Taevas
Why Pharmaceuticals Companies Choose Taevas
0+
Markets
0+
Registrations
0
Service Lines
0%
Compliance
Deep Therapeutic Expertise
Our regulatory and medical affairs teams have hands-on experience across 18 therapeutic categories, ensuring your dossier is prepared by specialists who understand the clinical nuances reviewers scrutinise most.
Pre-Built Distributor Networks
Taevas maintains qualified, audited pharmaceutical distributor relationships in 24+ markets so your brand enters an active commercial channel from the day of registration approval.
In-Country Medical Teams
Local medical science liaisons, KOL managers, and regulatory affairs officers operate in each market, providing ground-level execution that remote consultants simply cannot replicate.
Concurrent Regulatory and Commercial Execution
We prepare commercial infrastructure — supply chain, distributor agreements, and KOL mapping — during the regulatory review period so there is zero lag between approval and first sale.
Proven Multi-Jurisdiction Track Record
With over 340 drug registration filings managed across diverse regulatory regimes, Taevas brings a pattern-recognition advantage that consistently reduces approval timelines and resubmission rates.
Full Pharmacovigilance & Post-Market Compliance
Taevas manages post-marketing surveillance, adverse event reporting, and renewal obligations in every market, protecting your licence and ensuring continuous regulatory compliance throughout the product lifecycle.
Case Highlights
What Success Looks Like
/case-studies/cardiology-gcc-registration
Cardiology Brand Registered Across 6 GCC Markets
Prescription Cardiovascular Drug
Full marketing authorisation secured in Saudi Arabia, UAE, Kuwait, Bahrain, Oman, and Qatar within 14 months, with distributor activation and hospital formulary listing completed within 3 months of first approval.
/case-studies/generic-antibiotic-apac-launch
Generic Antibiotic Portfolio Launched in 4 APAC Markets
Generic Oral Antibiotics
Abbreviated dossier filings in India, Indonesia, Vietnam, and Philippines completed in parallel, achieving first market approval in 9 months and combined first-year sales exceeding initial volume projections by 28%.
/case-studies/biosimilar-oncology-emerging-markets
Biosimilar Oncology Product Entered Emerging Markets
Biosimilar Monoclonal Antibody
Regulatory strategy and comparability dossier designed for Brazil, South Africa, and Egypt; registration achieved in all three markets within 18 months with cold-chain logistics and oncology KOL programme activated at launch.
Get Started
Ready to Take Pharmaceuticals Global?
Whether you are filing in a single new market or executing a multi-region launch programme, Taevas provides the regulatory expertise, distributor access, and in-country medical teams to get your pharmaceutical brand to patients faster and compliantly.
Free market entry feasibility assessment
Regulatory pathway and timeline scoping at no cost
Immediate access to 24+ in-country specialist teams
No obligation consultation with a pharmaceutical market access expert